Briefing
Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer.
3-year bladder-intact survival among cCR after four rounds of systemic therapy: 69%.
- Design: Exploratory liquid biopsy in the gem/cis/nivo bladder-sparing trial; tumor-informed academic assay; authors note relatively small sample.
- Assay: Tumor-informed academic ctDNA and utDNA assay
Proc Natl Acad Sci USA 2026;123(8):e2533449123.PubMed 41706890